Aspen Neuroscience (ASPE) vs Avalo Therapeutics (AVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avalo Therapeutics is the larger company by market cap ($390.9 million vs $361.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASPE | AVTX |
|---|---|---|
| Share price | $12.42 | $6.76 |
| Market cap | $361.16M | $390.88M |
| 1-day change | +0.24% | +0.15% |
| YTD return | — | -62.78% |
| 1-year return | — | -62.09% |
| 5-year return | — | -99.89% |
| EPS (TTM) | $-4.89 | $-2.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $59.00K |
| Revenue growth (YoY) | — | -86.62% |
| Net income (latest FY) | — | $-78.26M |
| Operating margin | — | -123601.69% |
| Net margin | — | -132642.37% |
| 52-week high | $14.90 | $24.27 |
| 52-week low | $11.20 | $6.53 |
| Distance from 52-week high | -16.64% | -72.15% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +414.79% |
| Average volume | 352.42K | 1.80M |
| Shares outstanding | 29.08M | 57.82M |
| Employees | 120 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aspen Neuroscience
ASPE stock →Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
ASPE vs AVTX FAQ
Which is bigger, Aspen Neuroscience or Avalo Therapeutics?
Avalo Therapeutics (AVTX) is larger, with a market capitalization of $390.88M compared with $361.16M for Aspen Neuroscience (ASPE).
Are Aspen Neuroscience and Avalo Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.